Navigation Links
NeoStem Selected to Present at American Society for Apheresis
Date:5/28/2010

NEW YORK, May 28 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, announced that the Company's Director of Clinical Affairs and Apheresis, Lee Clough, BSN, RN, HP (ASCP), has been selected to present at the American Society for Apheresis (ASFA) 2010 Annual Meeting on Friday, May 28, 2010.

ASFA is an organization of physicians, scientists, and allied health professionals whose mission is to lead the field of apheresis through patient and donor care, research, education, and advocacy. Ms. Clough's presentation, entitled "Leaders Developing Leaders", will define the leadership role and discuss how to identify and train effective leaders to successfully manage the practice of apheresis medicine. Based on her experience at NeoStem and prior work at Children's National Medical Center as the Manager of the Blood Donor Center and Therapeutic Apheresis, Ms. Clough will discuss how to effectively combine the necessary technical skills and critical leadership skills to successfully manage internal and external relationships in apheresis medicine.

"As a pioneer in the field of autologous adult stem cell collection, our collection centers have been using the minimally invasive apheresis technique to extract stem cells from the body. We are proud to share our experience and knowledge in the area to help advance the apheresis field," said Robin Smith, M.D., NeoStem's CEO and Chairman of the board of directors. "NeoStem remains committed to expanding its adult stem cell collection network to help healthy individuals collect and store their cells for future use and is on track to have 10 stem cell collection centers in the U.S. by the end of the year."

NeoStem's minimally invasive adult stem collection procedure uses the mobilization process to increase the number of stem cells in the blood circulation. Then through apheresis, a painless and safe procedure, the stem cells are separated and collected for storage. The remaining cells are immediately returned to the blood circulation. The collected stem cells are stored in a cryo-preservation tank, and may be used for new regenerative therapies in the future.

ASFA is an organization of physicians, scientists, and allied health professionals whose mission is to lead the field of apheresis through patient and donor care, research, education, and advocacy. The vision of ASFA is to be the pre-eminent forum for the dissemination of evidenced-based knowledge, introduction of new information, and the exchange of new ideas in the field of apheresis medicine. The organization serves as the voice of investigators and practitioners to advance the development and delivery of programs and services in the field of apheresis medicine, benefiting patients, donors, and the general public.

About NeoStem, Inc.

NeoStem, Inc. is engaged in the development of stem cell-based therapies, pursuit of anti-aging initiatives and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company also has licensed various stem cell technologies, including a worldwide exclusive license to VSEL(TM) technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: http://www.neostem.com .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the ability to expand the Company's adult stem cell collection network, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010 and the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 17, 2010, as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

    For more information, please contact:

    NeoStem, Inc.
     Robin Smith, CEO
     Phone: +1-212-584-4174
     Email: rsmith@neostem.com
     Web:   http://www.neostem.com

    CCG Investor Relations, Inc.
     Lei Huang, Account Manager
     Phone: +1-646-833-3417
     Email: lei.huang@ccgir.com
     Web:   http://www.ccgirasia.com

     Crocker Coulson, President
     Phone: +1-646-213-1915
     Email: crocker.coulson@ccgir.com


'/>"/>
SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. NeoStems Advanced Adult Stem Cell Technology to be Featured at Upcoming Conference
2. NeoStem to Ring Opening Bell at New York Stock Exchange on May 27, 2010
3. NeoStem Announces Conversion of Convertible Preferred Stock by Principal Shareholder
4. NeoStem Provides Update on its Pharmaceutical Subsidiary Suzhou Erye
5. NeoStem, Inc. to Present at NASDAQ MarketSite
6. NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology
7. NeoStem Appoints Deloitte & Touche as New Independent Registered Public Accounting Firm
8. NeoStem Announces Presentation Time Change at Roth Capital Partners 22nd Annual OC Growth Stock Conference
9. NeoStem Enters into SRA with University of Michigan; Funding from NIH Stem Cell Research Grant
10. NeoStem Prices Public Offering of 5,000,000 Shares of Common Stock
11. Busy Southwestern Orthopedic Practice Joins the NeoStem Stem Cell Collection Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 2016 Beike Biotechnology, the Shenzhen ... a ceremony in late 2015 to mark their successful ... 2016. --> --> ... Personalized Cell Therapy" was hosted by the Shenzhen Cell ... subsidiaries of Beike Biotechnology Co., Ltd. ...
(Date:2/4/2016)... , Feb. 4, 2016  Spherix Incorporated (Nasdaq: ... the fostering and monetization of intellectual property, today provided ... Uniden in the Northern District of Texas ... forward.  Inter Partes Re-examination ("IPR") ... Patent Office.  The IPR was initiated on only certain ...
(Date:2/3/2016)... , Feb. 3, 2016   ViaCyte, ... with the first pluripotent stem cell-derived islet replacement ... in clinical-stage development, today announced that ViaCyte and ... Companies of Johnson & Johnson, have agreed to ... into ViaCyte.  The agreement provides ViaCyte with an ...
(Date:2/3/2016)... 3, 2016 New Jersey Health Foundation (NJHF) ... million for researchers in New Jersey ... that demonstrates exciting potential.   James ... the New Jersey Health Foundation Research Grant Program ... educational institutions— Princeton University, Rutgers University, Rowan University ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016  Based on ... Frost & Sullivan recognizes US-based Intelligent Retinal Imaging ... & Sullivan Award for New Product Innovation. IRIS, ... North America , is poised ... rapidly growing diabetic retinopathy market. The IRIS technology ...
(Date:2/1/2016)... 2016  Today, the first day of American Heart ... develop a first of its kind workplace health solution ... In the first application of Watson ... ), and Welltok will create a new offering that ... analytics, delivered on Welltok,s health optimization platform. The effort ...
(Date:1/28/2016)... SAN JOSE, Calif., Jan. 28, 2016 Synaptics (NASDAQ: ... financial results for its second quarter ended December 31, 2015. ... the second quarter of fiscal 2016 increased 2 percent compared to ... the second quarter of fiscal 2016 was $35.0 million, or $0.93 ... Non-GAAP net income for the first quarter of fiscal 2016 ...
Breaking Biology News(10 mins):